Details of Roche's positive Phase III APHINITY trial examining use of Perjeta (pertuzumab), Herceptin (trastuzumab) and chemotherapy together in the adjuvant treatment of breast cancer underwhelmed analysts at this year's ASCO meeting in Chicago and prompted many to say the combo's use is likely to be limited to node-positive patients.
APHINITY's aim was to show that adding Perjeta would significantly improve invasive disease-free survival rates in women with early HER2-positive breast cancer